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Background: Cadherins are calcium-dependent cell-to-cell adhesion glycoproteins playing a critical role in the
formation and maintenance of normal tissue architecture. In normal mammary gland, E-cadherin is expressed by
luminal epithelial cells, while P-cadherin is restricted to myoepithelial cells. Changes in the expression of classical
E- and P-cadherins have been observed in mammary lesions and related to mammary carcinogenesis. P-cadherin
and E-cadherin expressions were studied in a series of feline normal mammary glands, hyperplastic/dysplastic
lesions, benign and malignant tumours by immunohistochemistry and double-label immunofluorescence.
Results: In normal tissue and in the majority of hyperplastic/dysplastic lesions and benign tumours, P-cadherin was
restricted to myoepithelial cells, while 80% of the malignant tumours expressed P-cadherin in luminal epithelial cells.
P-cadherin expression was significantly related to high histological grade of carcinomas (p <0.0001), tumour necrosis
(p = 0.001), infiltrative growth (p = 0.0051), and presence of neoplastic emboli (p = 0.0401). Moreover,
P-cadherin positive carcinomas had an eightfold likelihood of developing neoplastic emboli than negative
tumours. Cadherins expression profile in high grade and in infiltrative tumours was similar, the majority expressing
P-cadherin, regardless of E-cadherin expression status. The two cadherins were found to be co-expressed in carcinomas
with aberrant P-cadherin expression and preserved E-cadherin.
Conclusions: The results demonstrate a relationship between P-cadherin expression and aggressive biological behaviour
of feline mammary carcinomas, suggesting that P-cadherin may be considered an indicator of poor prognosis in this
animal species. Moreover, it indicates that, in queens, the aberrant expression of P-cadherin is a better marker of
mammary carcinomas aggressive behaviour than the reduction of E-cadherin expression. Further investigation
with follow-up studies in feline species should be conducted in order to evaluate the prognostic value of
P-cadherin expression in E-cadherin positive carcinomas.
Keywords: Feline mammary tumours, Invasion, P-cadherin, E-cadherinBackground
Cadherins are calcium-dependent cell-to-cell adhesion
glycoproteins with critical roles in the formation and
maintenance of normal tissue architecture [1-4], including
in normal mammary gland [4-7]. E-cadherin (epithelial)
and P-cadherin (placental), are the best characterised
members of the cadherin superfamily [8], similarly
expressed in normal mammary epithelium of different* Correspondence: fgartner@ipatimup.pt
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unless otherwise stated.species, namely human [4,6,9-13], canine [14-17] and
feline [18-20]: E-cadherin is expressed by luminal epithe-
lial cells while P-cadherin is restricted to myoepithelial
cells. Changes in their expression have been observed
in mammary tumours and related to mammary car-
cinogenesis, both in humans [5,9,11-13,21-27], dogs
[14,16,17,28-30], as well as in cats [18-20,31,32]. Loss
of expression and/or abnormal function of E-cadherin
increase the ability of cells to invade neighbouring
tissues, thus favouring mammary tumour progression and
spread [4,13,33-35], whereas overexpression of P-cadherin
is related to increased cell proliferation, motility, inva-
siveness, and metastatic progression, thus being con-
sidered an invasion-promoting protein in breast cancerl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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anti-tumoural and anti-metastatic effects, suggesting
that interrupting the P-cadherin signalling pathway
may be a novel therapeutic approach for breast cancer
[5,39,40].
Mammary gland tumours are the third most common
neoplasm in queens and have been proposed as excellent
model for the study of human mammary carcinogenesis,
due to histopathological and clinical similarities with
human breast cancer [41,42]. As opposed to the large body
of knowledge on E- and P-cadherin expressions in human
breast carcinomas, there are only a few studies of these
molecules in feline mammary tumours [18-20,31,32,43],
and their role is still poorly understood in this species.
Studies on E-cadherin protein in feline mammary tumours
demonstrated its reduction or absent expression in carcin-
omas when compared to benign lesions [18,19,31,32]. The
prognostic value of this molecule in feline carcinomas is
still controversial: while no statistically significant associ-
ation between E-cadherin expression and tumour histo-
logical grade has been found [31], one study demonstrated
a negative correlation between E-cadherin expression and
regional lymph node metastases at the time of diagnosis
[31], however another revealed no correlation between the
expression of E-cadherin and survival, recurrence or
metastases [19].
To the best of our knowledge, only one study addressed
the P-cadherin expression in feline mammary tumours,
demonstrating that the protein is aberrantly expressed
by neoplastic epithelial cells in malignant tumours and
significantly associated to high grade carcinomas [20].
The purposes of this study were to examine the
expression of P-cadherin in a series of normal mammary
gland tissues and spontaneous hyperplastic and tumour
mammary lesions, and to determine its relationship with
the expression of E-cadherin as well as tumour clinico-
pathological features with recognized prognostic value




Samples from 75 queens with naturally occurring mam-
mary lesions, surgically excised with curative intents, and
nine normal mammary glands (obtained from queens that
were humanely euthanized for reasons not related to a
neoplastic disease) were included in this study. In each
case an informed consent was granted by the owners. All
specimens were fixed in 10% neutral buffered formalin.
After tissue dehydration and embedding in paraffin wax,
sequential 2 μm sections were cut from each block. One
section was stained with haematoxylin and eosin (H&E)
for routine histological examination and diagnosis, and
subsequent sections were used for immunohistochemicalstudies. When available, local and regional lymph nodes
were processed and examined for the presence of
metastases.
The histological classification of tumours was independ-
ently performed by three observers (ACF, PDP and FG)
based on the criteria of the World Health Organization
(WHO) for the histological classification of mammary
tumours of domestic animals [50].
Carcinomas were graded in accordance with the Not-
tingham grading system for human breast carcinomas [51].
Grading was based on the assessment of three morpho-
logical features: degree of tubule formation, nuclear
pleomorphism, and mitotic counts, and tumours were
classified as grade I (well differentiated), grade II (mod-
erately differentiated) and grade III (poorly differenti-
ated) [51]. Variables with known prognostic value, such
as the mode of growth (infiltrative or expansive), tumour
largest diameter (<2 cm, 2–3 cm, >3 cm), presence of
necrosis, skin ulceration, lymph node metastases, and
presence of intravascular neoplastic emboli [41,44], were
also recorded.
Evaluation of P-cadherin and E-cadherin
immunohistochemistry labelling
Immunohistochemistry (IHC) was performed using a poly-
mer based system (Novolink Max Polymer Detection Sys-
tem, Product No: RE7280-K Leica Biosystems, Newcastke,
UK), according to the manufacturer’s instructions. Sec-
tions were dewaxed in xylene, rehydrated through graded
alcohols and treated with extran for 10 minutes in micro-
wave oven for antigen retrieval. Endogenous peroxidase
activity was blocked by treating the sections with hydro-
gen peroxide 3% in methanol for 10 minutes and rinsed in
Tris-buffered saline (TBS, pH 7.6, 0.5 M). Sections were
incubated overnight at 4°C in a humid chamber with a
specific mouse anti-human monoclonal antibody against
P-cadherin (clone 56, BD Transduction Laboratories,
Lexington, Kentucky, USA) directed at the extracellular
domain of this adhesion molecule, and a specific mouse
anti-monoclonal antibody against E-cadherin (clone
4A2C7, Zymed/Invitrogen, Camarillo, CA, USA) that
recognizes the cytoplasmic domain of this molecule.
The antibodies were diluted 1:50 in TBS with 5% bo-
vine serum albumin (BSA). Labelling was visualized
with 3,3’-diaminobenzidine (DAB) incubated at room
temperature and sections were then counterstained
with Mayer’s haematoxilin, dehydrated and mounted.
For negative controls, the primary antibody was re-
placed by TBS. Sections of feline normal mammary
gland were used as positive controls. In the sections of
mammary lesions, adjacent normal mammary tissues or
skin were also used as internal positive controls.
In the lymph nodes sections, additional immunohisto-
chemical analysis was performed in order to determine
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by Matos et al. [52]. However, we used the antibody anti-
pancytokeratin AE1/AE3 and anti-p63 protein, since p63
protein is a sensitive and highly specific marker of myoe-
pithelial cells [53].
Assessment of P-cadherin expression was based on a
semi quantitative analysis, according to the percentage of
immunoreactive luminal epithelial cells with membranous
and/or cytoplasmic patterns, and graded as 0 - <10%,
1 - 10-25%, 2 - 26-50% and 3 - >50%. For statistical ana-
lysis, cases with less than 10% positive luminal epithelial
cells were considered negative and those with ≥10%
stained cells were considered positive [16,20].
E-cadherin expression was assessed semi quantitatively
in accordance with the percentage of immunoreactive
luminal epithelial cells with membranous labelling, and
graded as 0 - <25%, 1 - 25-50%, 2 - 51-75% and 3 - >75%
[54]. Cases with >75% stained cells were considered to
have preserved expression and those with ≤75% positive
cells as having reduced expression of E-cadherin [55].
To evaluate the combined expression of P-cadherin and
E-cadherin, samples were grouped according to the
expression of both molecules as P+E+, P+E−, P−E+, and
P−E−, (P+ = P-cadherin positive; P− = P-cadherin negative;
E+ = Preserved E-cadherin; E− = Reduced E-cadherin) [56].
Evaluation of P-cadherin and E-cadherin double-labelling
immunofluorescence
Double-label immunofluorescence (DIF) was performed
for simultaneous visualization of P- and E-cadherin ex-
pressions. Tissue sections of normal mammary gland,
hyperplastic/dysplastic lesions, benign and malignant
mammary tumours were selected and sections with neo-
plastic intravascular emboli and lymph node metastases
were also included.
Tissue sections were dewaxed in xylene, rehydrated
through a series of graded alcohols and treated with
extran for 10 minutes in microwave oven for antigen re-
trieval. Then, tissues sections were blocked with 10%
BSA for 20 minutes, followed by incubation with the pri-
mary antibodies mouse anti P-cadherin (mouse anti-
human monoclonal antibody against P-cadherin, clone
56, BD Transduction Laboratories, Lexington, Kentucky,
USA) and rabbit anti E-cadherin (rabbit anti-human
monoclonal antibody against E-cadherin, clone 24E10,
Cell Signaling Technology, MA, USA) diluted 1:50 and
1:100, respectively, in 5% BSA for two hours in a wet
chamber. After washing in phosphate buffered saline
(PBS), slides were incubated with Alexa Fluor® 488 goat
anti-mouse IgG (A11029, Life Technology, Carlsbad,
CA, USA) and Alexa Fluor® 594 goat anti-rabbit IgG
(A11037, Life Technology, Carlsbad, CA, USA) second-
ary antibodies diluted 1:500 in 5% BSA, for one hour.
Washes were performed with PBS and slides incubatedwith 4,6-diamidine-2-phenylindolendihydrochoride (DAPI)
100 μg/mL for 15 minutes. Slides were mounted in
glycerol-based Vectashield medium (Vector, Burlingame,
CA, USA).
Immunostained sections were analyzed by fluorescence
microscopy (Zeiss Imager Z1 microscope) with appropri-
ated filters. Separate images for Alexa 488 and Alexa 594
were captured at ×200 magnification and then merged to
allow for the visualization of P-cadherin and E-cadherin
double immunostaining. For negative controls, the pri-
mary antibody was replaced by PBS.
Statistical methods
Data was organized in contingency tables and the likeli-
hood ratio chi-square test of associations was used to de-
termine the significance of the relationship between the
expression of the cadherins and the tumours’ clinicopatho-
logical parameters. Whenever biologically consistent, 2×2
tables of contingency were built and Fisher’s exact test was
performed. The odds ratio was calculated to estimate the
relative risk of lymph node metastasis and neoplastic intra-
vascular emboli in tumours expressing P- and E-cadherin
molecules, with a confidence interval of 95%. All statistical
analysis was performed using SAS/STAT, 1989 (SAS Insti-
tute Inc., Cary, NC, USA) [57] and, in all instances, p <0.05
was considered to be statistically significant.
Results
The present study comprised 9 normal mammary gland
samples, 13 hyperplastic/dysplastic lesions (7 fibrocystic
diseases and 6 fibroadenomatous changes), 10 benign
tumours (7 simple adenomas and 3 fibroadenomas) and
60 malignant tumours (32 tubulopapillary carcinomas,
16 solid carcinomas, 4 cribriform carcinomas, 6 mucin-
ous carcinomas and 2 carcinosarcomas). Seven malig-
nant tumours were grade I, 25 grade II and 28 grade
III. Twenty-one carcinomas (36.21%) had neoplastic intra-
vascular emboli and, within the 35 cases where lymph
nodes were available, 18 (51.43%) had metastases.
P-Cadherin and E-cadherin expression by
immunohistochemistry
In normal mammary tissue, the expression of P-cadherin
was restricted to myoepithelial cells surrounding lobular
and ductal structures (Figure 1Aa). However, in lobules
with secretory activity P-cadherin was present in the
cytoplasm of luminal epithelial cells as well as in the se-
cretion. A similar staining pattern to normal mammary
tissue was evident in the majority (84.62%) of hyperplas-
tic mammary lesions, although two fibroadenomatous
changes exhibited P-cadherin expression in 10 to 25% of
luminal epithelial cells. In benign tumours, P-cadherin
was restricted to myoepithelial cells in most cases (70%).
All 7 simple adenomas were P-cadherin negative while
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Figure 1 P- and E-cadherin expression by immunohistochemistry (IHQ) and by double-label immunofluorescence (DIF) in feline mammary
tissue. A. P-cadherin immunohistochemistry (IHQ) - (a) Normal mammary gland with strong expression of P-cadherin by myoepithelial cells and lack
of immunoreactivity in luminal epithelial cells. IHC. x400; (b) Strong P-cadherin expression in high atypical neoplastic cells from a grade III
tubulopapillary carcinoma. IHC. x200; (c) Neoplastic intravascular embolus showing strong P-cadherin expression. IHC. x400; (d) Lymph node
metastases showing P-cadherin expression by neoplastic cells. IHC. x100. B. P- and E-cadherin double-label immunofluorescence (DIF) - (a)
Normal mammary gland tissue with P-cadherin in myoepithelial cells (green colour) and E-cadherin in luminal epithelial cells (red colour).
DIF. x200; (b) Tubulopapillary carcinoma with tumour cell populations co-expressing P-cadherin and E-cadherin (yellow colour). DIF. x200; (c)
Neoplastic intravascular embolus. DIF. x200. and (d) lymph node metastatic cells. DIF. x200. with a pattern of expression similar to primary
malignant neoplasia, with tumour cell populations co-expressing P-cadherin and E-cadherin (yellow colour).
Figueira et al. BMC Veterinary Research 2014, 10:270 Page 4 of 10
http://www.biomedcentral.com/1746-6148/10/270the 3 fibroadenomas were positive, one with 10-25% and
the other two with 26-50% positive cells.
Within the 60 malignant tumours, 48 (80%) had aber-
rant luminal epithelial P-cadherin expression (Figure 1Ab),
most noticeable in the tumour periphery, in invasive clus-
ters, in tubulopapillary areas and in the most atypical cells
(large cells, with bizarre shapes, large nucleus, multiple
nucleolus). In mucinous carcinomas, the cells surrounding
mucus were P-cadherin positive although the mucus itself
was negative. P-cadherin expression was also observed in
squamous cells, particularly in the most undifferentiatedbasal cells, and in the mesenchymal cells component of
carcinosarcomas.
P-cadherin expression was analysed in the neoplastic
intravascular emboli of 16 malignant tumours (in 5 cases
no representative sections for immunohistochemical
evaluation were available) and 18 lymph node metastases.
Amongst the former, 13 (81.25%) were P-cadherin posi-
tive (Figure 1Ac) and 17 (94.4%) of the later were also
P-cadherin positive (Figure 1Ad).
E-cadherin was expressed at the membrane of more
than 75% acinar and ductal luminal epithelial cells of
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cells were E-cadherin negative. Eleven (84.6%) hyper-
plastic lesions preserved this pattern of expression, while
2 cases of fibrocystic disease had less than 75% positive
cells. Benign tumours preserved E-cadherin expression
by luminal epithelial cells, except in one simple adenoma
where only 51-75% of the epithelial cells were stained.
E-cadherin immunohistochemical expression was re-
duced in almost half (46.67%) of the malignant tu-
mours. Five of the 6 mucinous carcinomas showed
reduced E-cadherin expression, most obvious in the
areas with mucus secretion; the mucus itself did not
stain for E-cadherin. Squamous cells stained positive
while mesenchymal and myoepithelial cells were nega-
tive to this protein.
Intravascular emboli of 17 malignant tumours were
evaluated for E-cadherin expression (in 4 cases it was
not possible to obtain representative sections for evalu-
ation) and the protein was expressed by more than 75%
cells in 13 cases (76.5%). More than half (55.6%) of the
18 lymph node metastases had more than 75% cells
expressing E-cadherin.
P-cadherin and E-cadherin expression by double-labelling
immunofluorescence
The P-cadherin and E-cadherin double-labelling im-
munofluorescence analysis demonstrated that they were
expressed in normal, hyperplastic and benign mammary
tissues in different cell types, with luminal epithelial
cells expressing E-cadherin, while myoepithelial/basal
cells expressed P-cadherin (Figure 1Ba). In carcinomas
it was possible to observe aberrant P-cadherin expression
by luminal epithelial cells, frequently co-expressed with
E-cadherin (Figure 1Bb), particularly at the peripheral
invasive front. The same expression pattern was observed
in the intravascular neoplastic emboli (Figure 1Bc) and in
lymph node metastases (Figure 1Bd).
Relationship between the expression of P-cadherin,
E-cadherin and clinicopathological parameters
Benign and malignant tumours diverged significantly with
respect to both P- and E-cadherin immunoexpression,
with most of the malignant tumours (80%) overexpressing
P-cadherin and the vast majority of the benign tumours





Benign 10 7 3 9
Malignant 60 12 48 32
p 0.0029 0.0384When the combined expression of P- and E-cadherin was
considered, most (60%) of the benign tumours were P−/E+
while the most common pattern in malignant tumours
was P+/E− (41.67%).
In malignant tumours, there was a statistically signifi-
cant association between P-cadherin overexpression and
higher histological grade, presence of necrosis, infiltrative
mode of growth, and neoplastic intravascular emboli
(Table 2). In the majority of malignant tumours, the
expression of P-cadherin by neoplastic intravascular emboli
and lymph node metastases was similar to that observed in
corresponding primary tumours (81.25%, p = 0.0012 and
77.78%, p = 0.0008, respectively). Furthermore, the expres-
sion of P-cadherin was associated to a nearly 8.5 odds ratio
for vascular invasion.
The reduced expression of E-cadherin, although signifi-
cantly related to the malignant histological tumour type
(p = 0.0243), was not related with the other parameters;
neither there was a statistical significant association be-
tween the expression of E-cadherin in primary tumours
and in their neoplastic intravascular emboli and lymph
node metastases.
The P-cadherin/E-cadherin combined expression pat-
terns were significantly associated with histological
grade of carcinomas, mode of growth and presence of
necrosis. In fact, 71.4% of grade I tumours were P−/E+,
while nearly 90% of grade II and III tumours (n = 53)
were P+/E− (n = 25, 47.2%) or P+/E+ (n = 23, 43.4%). All
tumours with expansive growth were P−/E+, a staining pat-
tern that was present in less than 10% of the infiltrative
ones. Half of the tumours with necrosis were P+/E−, while
the most common pattern of non-necrotic cases was P−/E+
(41.67%).
Discussion
In the present work, feline normal mammary tissue pre-
sented E-cadherin expression in luminal epithelial cells
and P-cadherin in myoepithelial cells of lobular and
ductal structures, without any evidence of overlapping
between the two cadherins, similarly to what is described
in normal mammary gland tissue in humans [4,6,9-13],
dogs [14-17] and cats [18-20]. In lactating or pseudo-
lactating mammary tissue, P-cadherin immunoreactivity
was observed in the cytoplasm of luminal epithelial cells
and in luminal secretion, in line with data from previoust tumours
n P-cadherin/E-cadherin
Reduced +/+ +/− −/+ −/−
1 3 0 6 1
28 23 25 9 3
0.0027
Table 2 Cadherin expression profiles and clinicopathological parameters of malignant tumours
Clinicopathological parameters n P-cadherin E-cadherin P-cadherin/E-cadherin
Negative Positive Preserved Reduced +/+ +/− −/+ −/−
Histological type
Tubulopapillary carcinoma 32 8 24 16 16 11 13 5 3
Solid carcinoma 16 3 13 9 7 6 7 3 0
Cribriforme carcinoma 4 1 3 4 0 3 0 1 0
Mucinous carcinoma 6 0 6 1 5 1 5 0 0
Carcinosarcoma 2 0 2 2 0 2 0 0 0
p NS 0.0243 NS
Histological grade*
Grade I 7 7 0 5 2 0 0 5 2
Grade II 25 2 23 12 13 10 13 2 0
Grade III 28 3 25 12 13 13 12 2 1
p <0.0001 NS <0.0001
Mode of growth**
Expansive 3 3 0 3 0 0 0 3 0
Infiltrative 56 6 48 28 28 23 25 5 3
p 0.0051 NS 0.0044
Tumour largest diameter
<2 cm 33 7 26 19 14 13 13 6 1
2–3 cm 10 2 8 7 3 5 3 2 0
>3 cm 17 3 14 6 11 5 9 1 2
p NS NS NS
Ulceration
Absent 48 10 38 27 21 19 19 8 2
Present 12 2 10 5 7 4 6 1 1
p NS NS NS
Necrosis
Absent 12 7 5 9 3 4 1 5 2
Present 48 5 43 23 25 19 24 4 1
p 0.0010 NS 0.0026
Neoplastic intravascular emboli
Absent 37 11 26 19 18 11 15 8 3
Present 21 1 20 12 9 11 9 1 0
p 0.0401 NS NS
Odds ratio 8.4615 (1.0071-71.0959)
Lymph node metastases
Absent 17 3 14 10 7 7 7 3 0
Present 18 0 18 10 8 10 8 0 0
p NS NS NS
NS -not significant.
*According to Elston & Ellis 1998 [51].
**In one case the margins were not included in sample.
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[59]. It is believed that P-cadherin is not just an adhesion
molecule, also acting as a signalling protein involved inbreast tissue remodelling, and that its soluble fragment
present in human milk may result from the proteolysis of
the extracellular domain [58,59].
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by luminal epithelial cells was observed in carcinomas,
when compared to benign mammary tumours. Further-
more, P-cadherin expression was positive in all mucinous
carcinomas and carcinosarcomas a fact that points to a
basal/myoepithelial cell histogenesis origin or line of
differentiation of these tumour types [16,60,61], since
P-cadherin is a well-recognized biomarker of basal
mammary carcinomas in humans [6,62-65]. However,
the association between P-cadherin expression and the
histological type of carcinomas was not achieved in the
present study, has not been yet demonstrated in
humans [5] and is not consensual in other animal
models such as dogs [16,56]. A significant association was
found between P-cadherin expression and histological grade
of carcinomas, as previously reported by other authors
in human breast cancer [11,21,23,24,26,27,62,66-68]
and canine mammary tumours [16,56], suggesting that
this molecule may be regarded as a prognostic indicator of
aggressiveness in feline mammary carcinomas. Moreover,
P-cadherin expression was more evident in the most
periphery cells of the tumour and in the invasive clusters,
denoting its importance in invasion and re-enforcing its
value as a marker of adverse behaviour in feline mammary
carcinomas.
To the best of our knowledge, this is the first study
addressing the association between the expression of
P-cadherin and the invasive/metastatic capacity of feline
mammary tumours. All tumours with lymph node
metastases and all, except one, with evident neoplastic
intravascular emboli were P-cadherin positive, which
indicates that the aberrant expression of P-cadherin may
constitute an important step in the invasion/metastatic
process. This hypothesis is reinforced by the fact that
P-cadherin positive tumours were 8.46 times more
likely to invade vessels than negative tumours. How-
ever, this result must be regarded with caution, since
the wide confidence interval (CI) reveals a low preci-
sion of the estimate. Although in human breast cancer
P-cadherin overexpression has been associated with
decreased survival and relapse-free intervals [36,64],
other studies failed to find a significant association
between P-cadherin and lymph node metastases at the
time of diagnosis [11,21,27]; however, Gamallo et al.
[26] found an association between P-cadherin expression
and lymph node-positive breast tumours. In this study
we failed to establish a relationship between P-cadherin
expression and lymph node metastases. Our findings
suggest that, in spite of the importance of this cadherin
in infiltrative/invasive process (increased cell motility,
vascular invasion), the arrest and establishment of neo-
plastic cells in sites of metastases may require the acquisi-
tion of other morphological and functional features, not so
closely related to P-cadherin. To the best of our knowledgethere are no survival studies in feline mammary tumours
related with P-cadherin expression.
Nearly half of the carcinomas included in this series
exhibited reduced E-cadherin expression, a significant dif-
ference compared to benign tumours, where only one case
showed E-cadherin down-expression. An association was
also established between specific histological types of car-
cinomas and the E-cadherin expression pattern. All cribri-
form carcinomas and carcinosarcomas showed preserved
E-cadherin expression, while the majority of mucinous
carcinomas had a reduced expression of the protein. In
cats, E-cadherin expression has been documented to be
reduced in tubulopapillary [19], cribriform and solid car-
cinomas [18], although the statistical significance of such
associations has never been assessed. Moreover, several
studies demonstrated that a reduced/loss membrane
expression of E-cadherin is significantly associated with
histological types of mammary tumours, namely lobular
carcinomas in women [9,10,13,69] and solid carcinomas
in bitches [15,17,54,56,70]. In our study, E-cadherin
expression was not related to histological grade of carcin-
omas. In fact, the association between this two factors is
not consensual both in humans [9,10,71] and dogs [54,56]
and the studies performed in cats have not proved this
association, to date [19,31].
In the present study, the expression of E-cadherin was
not associated to the presence of neoplastic intravascular
emboli and lymph node metastases, corroborating the hu-
man breast cancer [4,9,10,72-74] and feline mammary tu-
mours [19,31] literature in which there is no consensus
regarding the prognostic value of E-cadherin. Further-
more, and in accordance with previous studies [72,75], the
pattern of E-cadherin expression differ between primary
tumours and their lymph node metastases, reinforcing the
concept that, during breast carcinoma progression, there
is a dynamic and reversible modulation of the E-cadherin
complex [4,76,77].
When analysing the combined expression of P- and
E-cadherins, two different patterns emerged: while 90%
of the benign tumours preserved the expression of
E-cadherin, irrespective of the P-cadherin status, 80%
of the malignant tumours exhibited an overexpression
of P-cadherin, independently of the E-cadherin staining
pattern. These results suggest that the abnormal expres-
sion of P-cadherin is a better indicator of the malignant
potential of feline mammary neoplasm than the loss of
E-cadherin. Furthermore, the combined expression of
P- and E-cadherin was significantly associated with the
histological grade of the tumours, with the majority (90%)
of grade II and III carcinomas exhibiting a P+/E+ or P+/E−
immunophenotype. The fact that half of the grade III P+
malignant tumours were also E+ deserves the evaluation
of the prognostic value of aberrant P-cadherin expression
in a context of preserved E-cadherin expression through
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breast cancer cells, the E- and P-cadherin co-expression
could be involved in a more aggressive biological behaviour,
and that the establishment of strong adhesion complexes is
compromised by the interaction of both molecules at the
cell membrane. Moreover, they demonstrate that E+/P+
cells have deregulated cadherin/catenin complexes at the
cellular membrane, when compared with cells expressing
only one of the cadherins and have a higher invasive cap-
acity. In fact, P-cadherin overexpression in an E-cadherin
wild type context leads to disruption of the interaction
between E-cadherin and intracellular catenins, an alter-
native mechanism for cancer invasion [5,74,78,79]. The
co-expression of both molecules was significantly cor-
related with high-grade, biologically aggressive, breast
carcinomas and poor patient survival [5,39,74].
The association between P- and E-cadherin expression
and four clinicopathological parameters with known prog-
nostic value in feline mammary tumours, namely ulceration
[46,47], necrosis [47], infiltrative growth [44], and tumour
largest diameter [47-49], was also addressed in this study.
Interestingly, the E- and P-cadherin immunostaining pat-
tern observed in infiltrative carcinomas was very similar to
the findings in grade III tumours, i.e. the majority express-
ing P-cadherin, and surprisingly, nearly half of the P+ infil-
trative carcinomas preserved E-cadherin expression. This is
in accordance with data from immunofluorescence analysis
that revealed P- and E-cadherin co-expression, particu-
larly at the malignant tumour periphery. When consid-
ered together (neoplastic intravascular emboli and/or
lymph node metastases), none of the invasive tumours
was P−/E−, suggesting that the simple reduction of
E-cadherin, when not accompanied by an aberrant
expression of P-cadherin, is insufficient for an invasive
tumour behaviour. Furthermore, more than half of the
P-cadherin positive tumours associated with vascular
emboli and lymph node metastases were also E-cadherin
positive. In fact, in P+/E+ malignant tumours, double
immunofluorescence evidenced a co-expression of the
two cadherins, a pattern also observed in the intravascular
neoplastic emboli and in lymph nodes metastatic cells.
These results reinforce the need for the study of the prog-
nostic value of P-cadherin positivity in tumours that pre-
serve E-cadherin expression in feline mammary species.
Besides its prognostic value, P-cadherin has been re-
cently considered as a therapeutic target. A highly se-
lective human monoclonal antibody against P-cadherin
(PF-03732010, Pfizer, Inc) may constitute a novel anti-
cancer therapy in high P-cadherin expressing tumours
[40]. Furthermore, azurin is pointed as a therapeutic
tool for poor-prognosis breast carcinomas overexpress-
ing P-cadherin in a wild type E-cadherin context [39].
Within this scenario, the highly aggressive P-cadherin posi-
tive feline mammary tumours with preserved E-cadherinexpression may benefit from one of these novel therapeutic
approaches.
Conclusions
The present study demonstrated an association between
the aberrant expression of P-cadherin and a malignant
phenotype, higher histological grade and invasive behav-
iour, suggesting that this protein may constitute a reliable
independent biomarker of poor prognosis in feline mam-
mary tumours. Moreover, it suggests that P-cadherin aber-
rant expression may represent a relevant prognostic factor,
being associated with an aggressive biological behaviour in
feline mammary carcinomas, better than the reduction of
E-cadherin expression. The prognostic value of P-cadherin
expression in E-cadherin positive carcinomas in feline
species should be evaluated in further investigation with
follow-up studies.
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